아미카신

용도

• Susceptible bacterial infections
• Susceptible bacterial infections in Greyhounds and sight hounds
• Sepsis
• Local infections (e.g., joints, bladder)
• Susceptible bacterial infections
• Sepsis
• Local infections (e.g., joints, bladder)

투여 방법

가능한 부작용

• Nephrotoxicity (tubular necrosis)
• Ototoxicity (vestibular and auditory dysfunction)
• Neuromuscular blockade (rare but possible)

주의사항 및 금기

• Animals with pre-existing reduced renal function (unless benefits outweigh risks)
• Dehydrated patients (without concurrent fluid therapy)
• > **Intravenous Administration:** IV doses should be given slowly, generally over 30-60 minutes. > **Fluid Therapy:** Concurrent fluid therapy is strongly advised to maintain glomerular filtration and reduce nephrotoxicity. > **Monitoring:** Therapeutic drug monitoring (peak and trough serum levels) should be considered to ensure efficacy and minimize toxicity, especially in neonates, geriatric patients, and those with compromised renal function.

약물 상호작용

• Beta-lactam antimicrobials (Penicillins, Cephalosporins): In vivo synergism against susceptible bacteria; however, they can cause in vitro inactivation of amikacin. Do not mix in the same syringe.
• Amphotericin B: Increased risk of severe nephrotoxicity.
• Furosemide: Increased risk of ototoxicity and nephrotoxicity.
• Heparin: In vitro inactivation of amikacin. Do not mix in the same syringe.
• Neuromuscular blocking agents: Potentiation of neuromuscular blockade.

자주 묻는 질문